Tonix Pharma Files 8-K on Operations and Other Events

Ticker: TNXP · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1430306

Sentiment: neutral

Topics: 8-K, financial-condition, operations

TL;DR

Tonix Pharma filed an 8-K on Oct 27, 2025, covering operations and other events. Details TBD.

AI Summary

Tonix Pharmaceuticals Holding Corp. filed an 8-K on October 27, 2025, reporting on its results of operations and financial condition, as well as other events. The filing does not contain specific financial figures or details about the 'other events' in the provided text.

Why It Matters

This filing indicates that Tonix Pharmaceuticals is providing updates on its financial status and other corporate developments to the SEC, which is crucial for investors to monitor.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not contain information that inherently increases risk.

Key Players & Entities

FAQ

What specific financial results are reported in this 8-K?

The provided text indicates the filing covers 'Results of Operations and Financial Condition' but does not detail specific financial figures.

What are the 'Other Events' mentioned in the filing?

The filing states 'Other Events' are reported, but the specific nature of these events is not detailed in the provided text.

When was this 8-K report filed?

The report was filed on October 27, 2025.

What is the principal executive office address for Tonix Pharmaceuticals Holding Corp.?

The principal executive offices are located at 26 Main Street, Chatham, New Jersey 07928.

What is the IRS Employer Identification Number for Tonix Pharmaceuticals Holding Corp.?

The IRS Employer Identification Number is 26-1434750.

Filing Stats: 1,186 words · 5 min read · ~4 pages · Grade level 14 · Accepted 2025-10-27 07:00:38

Key Financial Figures

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition. Tonix Pharmaceuticals Holding Corp. (the "Company") is disclosing selected preliminary operating results for the quarter ended September 30, 2025, and certain preliminary financial condition information as of October 24, 2025, as set forth below: The Company ended the quarter with approximately $190.1 million in cash and cash equivalents. As of October 24, 2025, the Company had 11,475,491 shares of common stock outstanding. The Company's net cash used in operating activities for the quarter ended September 30, 2025 was approximately $28.8 million compared to $18.8 million for the quarter ended September 30, 2024. The Company's capital expenditures for the quarter ended September 30, 2025, was approximately $1.0 million compared to $0 million for the quarter ended September 30, 2024. The Company's net loss for the quarter ended September 30, 2025, was approximately $32.0 million compared to $14.2 million for the quarter ended September 30, 2024. The Company's net revenue from the sale of its marketed products for the quarter ended September 30, 2025, was approximately $3.3 million compared to $2.8 million for the quarter ended September 30, 2024. The Company believes that its cash resources at September 30, 2025, and the net proceeds of $29.3 million that it received from equity offerings in the fourth quarter of 2025, will meet its planned operating and capital expenditure requirements into the first quarter of 2027. The above information is preliminary financial information for the quarter ended September 30, 2025 and subject to completion. The unaudited, estimated results for the quarter ended September 30, 2025 are preliminary and were prepared by the Company's management, based upon its estimates, a number of assumptions and currently available information, and are subject to revision based upon, among other things, quarter end closing procedures and/or adjustments, the completion of the Com

Financial Statements and Exhibits

Financial Statements and Exhibits. The Company expects to commence the U.S. commercial launch of Tonmya for the treatment of fibromyalgia in adults by the end of November 2025. The information included in Item 2.02 is incorporated herein by reference. Forward- Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, wheth

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing